메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

MOEA Takes Home 7 Awards at R&D100

18 Years, 100+ Awards: Taiwan's R&D Prowess Shines on Global Stage TAIPEI, Nov. 21, 2025 -- Taiwan's Ministry of Economic Affairs (MOEA) announced today (21st) that six technologies it funded have won seven awards at the 2025 R&D 100 Awards, often hailed as the "Oscars of Innovation." The award-winning technologies include three from the Industrial Technology Research Institute (ITRI), one from the Taiwan Textile Research Institute (TTRI), one from the Metal Industries Research & Development Centre (MIRDC) (which also received a Special Recognition award), and one
- 김갑성 기자
- 2025-11-21 16:30
Sisram Medical Launches Universkin by Alma in Hong Kong, Pioneering a New Era of AI-assisted Personalized Skincare

HONG KONG, Nov. 21, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, announced that Alma Lasers Ltd., a wholly-owned subsidiary of Sisram, has launched Universkin by Alma, the world's first AI-assisted skincare solution, in the Hong Kong market. With pioneering AI-assisted technology, Universkin by Alma enables practitioners to capture a facial image, pe
- 김갑성 기자
- 2025-11-21 16:15
Hong Kong hosts landmark International Genomic Medicine Symposium

[ 메디채널 김갑성 기자 ] 300 Industry Leaders Gather to Drive Medical Innovations and Showcase Hong Kong's Strengths HONG KONG, Nov. 21, 2025 -- The International Genomic Medicine Symposium (Symposium), jointly organised by the Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The Lancet Commission on Rare Diseases (LCRD) opened on November 17 at the Hong Kong Science Park. This prestigious event has attracted close to 300 industry professionals, including medical practitioners, scientists, and researchers from over 20 countries and regions. Participants include distin
- 김갑성 기자
- 2025-11-21 15:49
IEI Secures TFDA QMS Approval and ISO 13485 Certification, Reinforcing Audit-Ready Manufacturing for MedTech Design Transfers

[ 메디채널 김갑성 기자 ] Dual certifications streamline global design transfers and regulatory compliance. TAIPEI, Nov. 21, 2025 -- IEI Integration Corp. ("IEI"), a global provider of medical and industrial computing platforms, today announced that its New Taipei City (Xizhi) and Qidu (Keelung) facilities have passed inspection by the Taiwan Food and Drug Administration (TFDA) and been awarded Quality Management System (QMS) approval (Xizhi Certificate No. QMS2376、Keelung Certificate No. QMS2377), while maintaining ISO 13485:2016 certification. As one of Taiwan's manufacturers holdi
- 김갑성 기자
- 2025-11-21 15:35
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company's first cyclotron facility in the Asia Pacific region (APAC). TMS Yokohama will enable Telix to provide greater access to radiopharmaceuticals for Japanese patients, initially through clinical supply of TLX250-CDx (a kidney cancer imaging candidate), with plans to supply other Telix investigational and future commercial products, i
- 김갑성 기자
- 2025-11-21 14:22
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class team VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 21, 2025 -- NovaB
- 김갑성 기자
- 2025-11-21 13:46
National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving medicines for patients SINGAPORE, Nov. 21, 2025 -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that Medidata Health Record Connect and Medidata Rave Companion, both integral components of the Medidata Data Experience, will be available to a select set of National Cancer Institute (NCI) Lead Protocol Organizations (LPO). These solutions
- 김갑성 기자
- 2025-11-21 11:28
Dimora Medical Reaffirms Long-Term Commitment to Pressure Injury Patients on Worldwide Pressure Injury Prevention Day

NEW YORK, Nov. 21, 2025 -- Observed annually on the third Thursday of November each year, Worldwide Pressure Injury Prevention Day serves as a global reminder of the urgent need to prevent pressure injuries, also known as pressure ulcers or bedsores, among vulnerable populations. Established by the National Pressure Injury Advisory Panel (NPIAP) and supported by organizations worldwide, the day aims to raise public awareness, promote evidence-based prevention strategies, and highlight the importance of early intervention for individuals at risk, including those who are bedridden, wheelchair u
- 김갑성 기자
- 2025-11-21 11:14
Colebrook Bosson Saunders Launches Their First Sustainability Report

HONG KONG, Nov. 21, 2025 -- As the world turns its attention to the environment during COP30, Colebrook Bosson Saunders (CBS), the leader in workplace ergonomics, is underscoring the need for collective action, transparency, and responsibility by the private sector. To support customers and the industry advance positive change, the brand released its first Sustainability Report this year, setting bold 2030 targets that demonstrate its commitment to responsible, forward-focused business. Access the Sustainability Report 2025 here: https://cdn.shopify.com/s/files/1/0788/7
- 김갑성 기자
- 2025-11-21 09:00
페프로민 바이오, BAFFR-CAR T 'PMB-CT01' 데이터, 2025년 ASH 제67차 연례학회 구두 발표 2건 선정

어바인, 캘리포니아, 2025년 11월 21일 -- 재발•불응(r/r) B세포 악성 종양 치료를 위한 혁신 치료제를 개발하는 임상단계 바이오테크 기업 페프로민 바이오(PeproMene Bio, Inc.)가 자사 PMB-CT01(BAFFR-CAR T) 임상 1상 연구 초록 두 건이 2025년 미국혈액학회(American Society of Hematology, ASH) 연례학회에서 구두 발표로 채택됐다고 밝혔다. 해당 초록들은 고강도 사전 치료 이력이 있는 r/r B세포 급성 림프구성 백혈병(B-ALL) 및 r/r B세포 비호지킨 림프종(B-NHL) 환자를 대상으로 한 PMB-CT01의 초기 안전성 및 유효성 프로파일을 제시한다. 여기에는 기존 CD19 표적 치료에 실패했거나 CD19 음성 질환을 가진 환자도 포함된다. 임상 1상 단계적 용량증량 연구(NCT04690595, NCT05370430)의 중간 결과는 BAFF-R이 CD19 항원 소실을 극복하면서 내구성을 유지하고 독성이 낮은 차별화된 표적임을 시사한다. r/r B-NHL 안전성:PMB-CT01은 매우 우수한 내약성을 보였다. 1등급 초과의 사이토
- 김갑성 기자
- 2025-11-21 08:08

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분